export default [
  {
    brandName: '',
    chemicalName: 'mrna-1273',
    conditionOrDisease: 'covid-19',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'phase 1',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes: 'mrna-based vaccine',
    numSites: '2',
    otherPartners: 'cepi',
    phase: '1',
    preferredName: 'mrna-1273',
    productId: 1,
    productType: '',
    repurposed: 'new',
    sponsors: 'moderna,national institute of allergy and infectious diseases',
    status: 'ongoing',
    therapeuticApproach: 'unknown',
    trialId: 'nct04283461',
    siteLocations: [
      {
        name: 'Hospital Pkwy',
        city: 'San Jose',
        state: 'California',
        country: 'USA',
        lat: 37.239746,
        lon: -121.802344,
      },
      {
        name: 'Seoul Hospital',
        city: 'Seoul',
        state: '',
        country: 'South Korea',
        lat: 37.5665,
        lon: 126.978,
      },
    ],
  },
  {
    brandName: 'test',
    chemicalName: 'mrna-1272',
    conditionOrDisease: 'covid-19',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'phase 1',
    indication: 'covid-19',
    interventionType: 'treatment',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes: 'mrna-based vaccine',
    numSites: '2',
    otherPartners: 'cepi',
    phase: '1',
    preferredName: 'mrna-1273',
    productId: 1,
    productType: '',
    repurposed: 'new',
    sponsors: 'moderna,national institute of allergy and infectious diseases',
    status: 'ongoing',
    therapeuticApproach: 'unknown',
    trialId: 'nct04283461',
    siteLocations: [
      {
        name: 'Test',
        city: 'Test2',
        state: 'NY',
        country: 'USA',
        lat: 40.6643,
        lon: -73.9385,
      },
    ],
  },
]

export const ProdData = [
  {
    brandName: '',
    chemicalName: 'mrna-1273',
    conditionOrDisease: 'covid-19',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'phase 1',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes: 'mrna-based vaccine',
    numSites: '2',
    otherPartners: 'cepi',
    phase: '1',
    preferredName: 'mrna-1273',
    productId: 1,
    productType: '',
    repurposed: 'new',
    siteLocations:
      'kaiser permanente washington health research institute - seattle - washington,emory children\'s center - decatur - georgia',
    sources: [
      'https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins',
      'https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19',
      'https://clinicaltrials.gov/ct2/show/nct04283461?term=coronavirus+vaccine&draw=2',
      'https://clinicaltrials.gov/ct2/show/nct04283461?term=coronavirus+vaccine&draw=1',
      'https://clinicaltrials.gov/ct2/show/nct04283461?term=coronavirus+vaccine&draw=3',
      'https://clinicaltrials.gov/ct2/show/nct04283461?term=coronavirus+vaccine&draw=4',
      'https://clinicaltrials.gov/ct2/show/nct04283461?term=coronavirus+vaccine&draw=5',
      'https://clinicaltrials.gov/ct2/show/nct04283461?term=coronavirus+vaccine&draw=6',
      'https://clinicaltrials.gov/ct2/show/nct04283461?term=coronavirus+vaccine&draw=7',
      'https://corona.kpwashingtonresearch.org/',
    ],
    sponsors: [
      {
        sponsorId: '375ad6c4b12a03acefcf5e9b052423279351910a',
        sponsorName: 'Moderna',
      },
      {
        sponsorId: '69301ed353817a1eb80b77b32f82e5809965a871',
        sponsorName: 'National Institute of Allergy and Infectious Diseases',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'unknown',
    trialId: 'nct04283461',
  },
  {
    brandName: '',
    chemicalName: 'novavax vaccine',
    conditionOrDisease: '',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'subunit vaccines',
    notes:
      'not totally clear that it is prophylactic vaccine. p1 expected late spring',
    numSites: '',
    otherPartners: 'cepi',
    phase: '',
    preferredName: 'novavax vaccine',
    productId: 2,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-novavax-manufacture?field_nir_news_date_value[min]=',
      'https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development',
    ],
    sponsors: [
      {
        sponsorId: '605f6647f1bdd3849bac0626225a6effc774a373',
        sponsorName: 'Novavax Inc',
      },
      {
        sponsorId: 'f4d20a236175ba7e1926d1e68974b9e499bd94ed',
        sponsorName: 'Emergent BioSolutions Inc',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'bnt162',
    conditionOrDisease: '',
    countries: 'germany',
    countryCodes: 'deu',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes:
      'expect clinical testing in late april. note this drug is also being developed in china with fosun pharma. assumed this is in discovery as no explicit statements aboit preclinical found',
    numSites: '',
    otherPartners: 'polymun',
    phase: '',
    preferredName: 'bnt162',
    productId: 3,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine',
      'https://biontech.de/',
      'https://www.fiercebiotech.com/biotech/weeks-to-go-to-covid-19-vaccine-trial-biontech-lands-135m-deal-and-advances-pfizer-talks',
      'https://biontech.de/node/159',
    ],
    sponsors: [
      {
        sponsorId: '7c4d34cd18acefd9b97f8b918fe356fec61f94d6',
        sponsorName: 'Pfizer Inc',
      },
      {
        sponsorId: '633c14412c5bdb1e419eeef95aef4fe8eb93e2a1',
        sponsorName: 'BioNTech SE',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'imperial college london vaccine',
    conditionOrDisease: '',
    countries: 'united kingdon',
    countryCodes: '',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes: 'expect clinical testing in summer',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'imperial college london vaccine',
    productId: 4,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/',
    ],
    sponsors: [
      {
        sponsorId: '1a693dd5acf9f3ae07a65241da0b2f2102ed1377',
        sponsorName: 'Imperial College London',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: 'cellectra\u00ae',
    chemicalName: 'ino-4800',
    conditionOrDisease: 'covid-19',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes: '',
    numSites: '',
    otherPartners:
      'us dod,bill and melinda gates foundation,coalition for epidemic prepardness innovations funding',
    phase: '1',
    preferredName: 'ino-4800',
    productId: 5,
    productType: '',
    repurposed: 'new',
    siteLocations: 'united states',
    sources: [
      'https://www.precisionvaccinations.com/vaccines/ino-4800-dna-coronavirus-vaccine',
    ],
    sponsors: [
      {
        sponsorId: 'a28cb988e230163b5e185750856269de4f3cd2eb',
        sponsorName: 'Inovio Pharmaceuticals Inc',
      },
      {
        sponsorId: '2534fc505ec4a7e9f4871746ebd7fe5a84b18af8',
        sponsorName: 'Beijing Advaccine Biotechnology',
      },
      {
        sponsorId: '09820e27323251c097da890722d6b1060e453555',
        sponsorName: 'US Department of Defense',
      },
      {
        sponsorId: '8b02e4cb59e0603882788f6b09eece49a6f530e2',
        sponsorName: 'Ology Bioservices Inc',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'monoclonal antibodies',
    trialId: '',
  },
  {
    brandName: 'ad26 sars-cov-2',
    chemicalName: '',
    conditionOrDisease: '',
    countries: 'belgium',
    countryCodes: 'bel',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'gene therapies',
    notes: 'expect clinical testing no later than fall 2020',
    numSites: '',
    otherPartners: 'barda',
    phase: '',
    preferredName: 'ad26 sars-cov-2',
    productId: 6,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html',
      'https://milkeninstitute.org/sites/default/files/2020-03/covid19%20tracker%20new3-30-20.pdf',
      'https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5609467/',
      'https://www.sciencemag.org/news/2020/03/1-billion-bet-pharma-giant-and-us-government-team-all-out-coronavirus-vaccine-push',
    ],
    sponsors: [
      {
        sponsorId: '667987d4de01dd23efc5563684db4e2117b5d910',
        sponsorName: 'Janssen',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'sanofi vaccine',
    conditionOrDisease: '',
    countries: 'france',
    countryCodes: 'fra',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'subunit vaccines',
    notes:
      'they are repurposing vaccines that have been preclinically tested for sars - hence i have put the current status as preclinical',
    numSites: '',
    otherPartners: 'barda',
    phase: '',
    preferredName: 'sanofi vaccine',
    productId: 7,
    productType: '',
    repurposed: 'repurposed-not approved',
    siteLocations: '',
    sources: [
      'http://www.news.sanofi.us/2020-02-18-sanofi-joins-forces-with-u-s-department-of-health-and-human-services-to-advance-a-novel-coronavirus-vaccine',
      'https://www.google.com/search?q=sanofi+pasteur+headquarters&rlz=1c5chfa_engb854gb854&oq=sanofi+pastuer+head&aqs=chrome.1.69i57j0l7.7080j1j9&sourceid=chrome&ie=utf-8',
      'https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00',
    ],
    sponsors: [
      {
        sponsorId: '551135a9f6ade78853bbd5fdbd66283c70e2f776',
        sponsorName: 'Sanofi',
      },
      {
        sponsorId: 'e0bdadccf43d8757f432e13f07484a9d84e509c7',
        sponsorName: 'BARDA',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: 'regeneron therapeutic',
    chemicalName: '',
    conditionOrDisease: '',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'discovery',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes:
      'plan to start human trials in summer 2020. technique was previously used to develop successful regn-eb3 ebola treatment.',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'regeneron therapeutic',
    productId: 8,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody',
      'https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody',
      'https://www.regeneron.com/covid19',
    ],
    sponsors: [
      {
        sponsorId: 'a7cbf979a98fdc448b32b211e3d5e8264875995e',
        sponsorName: 'Regeneron',
      },
      {
        sponsorId: 'fc75c1a3f384fb950104d48eeee9665cc126614f',
        sponsorName: 'HHS',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'monoclonal antibodies',
    trialId: '',
  },
  {
    brandName: 'vaxart vaccine',
    chemicalName: 'vaxart vaccine',
    conditionOrDisease: '',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'discovery',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'subunit vaccines',
    notes:
      'oral tablet. recombinant vaccine. plan to initiate phase i trial in second half of 2020.',
    numSites: '',
    otherPartners: 'emergent',
    phase: '',
    preferredName: 'vaxart vaccine',
    productId: 9,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions',
    ],
    sponsors: [
      {
        sponsorId: '80a6767f041a7aef5269023e2f54d91aa27066da',
        sponsorName: 'Vaxart',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'university of queensland vaccine',
    conditionOrDisease: '',
    countries: 'australia',
    countryCodes: 'aus',
    currentStatus: 'discovery',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'subunit vaccines',
    notes: 'plans for clinical trials in july in queensland.',
    numSites: '',
    otherPartners:
      'cepi,the queensland government,paul ramsay foundation,a2 milk company',
    phase: '',
    preferredName: 'university of queensland vaccine',
    productId: 10,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine',
      'https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html',
    ],
    sponsors: [
      {
        sponsorId: '83489a1277ddc5cf37050ab7342ac914748abdc2',
        sponsorName: 'University of Queensland',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'vido-intervac vaccine candidate',
    conditionOrDisease: '',
    countries: 'canada',
    countryCodes: 'can',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'unknown',
    notes: '',
    numSites: '',
    otherPartners: 'canadian federal government',
    phase: '',
    preferredName: 'vido-intervac vaccine candidate',
    productId: 11,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.technologynetworks.com/tn/news/12m-awarded-for-new-covid-19-vaccine-manufacturing-efforts-332506',
      'https://www.cbc.ca/news/health/coronavirus-covid-19-vido-intervac-saskatchewan-vaccine-1.5508114?__vfz=medium%3dsharebar',
    ],
    sponsors: [
      {
        sponsorId: '52a54b2f0746508531714d16ee2993cb5ff764a5',
        sponsorName: 'International Vaccine Centre',
      },
      {
        sponsorId: '7ffe768f0f9cf49a08e526fad894319b1b874d64',
        sponsorName: 'University of Saskatchewan',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'unknown',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'chadox1 ncov-19',
    conditionOrDisease: 'covid-19',
    countries: 'united kingdom',
    countryCodes: 'gbr',
    currentStatus: 'phase 1',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'subunit vaccines',
    notes: '',
    numSites: '',
    otherPartners: 'university of oxford',
    phase: '1',
    preferredName: 'chadox1 ncov-19',
    productId: 12,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://economictimes.indiatimes.com/news/international/world-news/oxford-university-begins-enrolling-over-500-volunteers-for-coronavirus-vaccine-trial/articleshow/74864754.cms',
      'https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development',
      'https://www.clinicaltrials.gov/ct2/show/nct04324606',
      'https://www.jackfm.co.uk/news/oxfordshire-news/oxford-uni-clinical-trials-for-covid-19-vaccine-could-begin-next-month/',
    ],
    sponsors: [
      {
        sponsorId: 'b91bf90d7d04e343ba36d6ff216e09bcbdf60f8f',
        sponsorName: 'Jenner Institute',
      },
      {
        sponsorId: 'd1cf38e4f7d70b602814433c015565b664ba5fa5',
        sponsorName: 'Oxford Vaccine Group',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'unknown',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'niv pune vaccine candidate',
    conditionOrDisease: '',
    countries: 'india',
    countryCodes: 'ind',
    currentStatus: 'discovery',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'unknown',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'niv pune vaccine candidate',
    productId: 13,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.livemint.com/news/india/covid-19-india-becomes-5th-country-globally-to-isolate-virus-strain-11584102221498.html',
    ],
    sponsors: [
      {
        sponsorId: 'db62a75311d8473967f358928e8460e901771f76',
        sponsorName: 'National Institute of VirologyPune',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'unknown',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: 'china',
    countryCodes: 'chn',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes: 'animal testing',
    numSites: '',
    otherPartners: 'stermirna therapeutics co. ltd',
    phase: '',
    preferredName:
      'chinese_center_for_disease_control_and_prevention_tongji_university_school_of_medicine_stermirna_therapeutics_co_ltd-14',
    productId: 14,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: ['http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm'],
    sponsors: [
      {
        sponsorId: '52d02c14b6240aabfbdc4ded5640e554e55e2ca1',
        sponsorName: 'Chinese Center for Disease Control and Prevention',
      },
      {
        sponsorId: '5f73dfa644e6480f6632298372551fe30f6bfc70',
        sponsorName: 'Tongji University School of Medicine',
      },
      {
        sponsorId: '3020404bf63cebc77d8c10a2cc920657b5249ee2',
        sponsorName: 'Stermirna Therapeutics Co Ltd',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'unknown',
    trialId: '',
  },
  {
    brandName: 't89',
    chemicalName: 'dantonic',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'dantonic',
    productId: 112,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '0dda51f9c95a47c39d878234d93d16d7902c83f1',
        sponsorName: 'Tasly Pharmaceuticals',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'monoclonal antibodies',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'monoclonal_antibodies',
    productId: 113,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '8fac0a09b519ab63b6b2df21b2f9466e27a8b413',
        sponsorName: 'AztraZeneca PLC',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'monoclonal antibodies',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'monoclonal_antibodies',
    productId: 114,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '5eb637ba4abb840b8fb5b72cd2a33b52071b7382',
        sponsorName: 'Celtrion',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'monoclonal antibodies',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'monoclonal_antibodies',
    productId: 115,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '9703ee3af6deed8f220b20ca2458478aa2c73fdf',
        sponsorName: 'Dyadic International',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'university of hong kong vaccine',
    chemicalName: 'delns1-sars-cov2-rbd laiv',
    conditionOrDisease: '',
    countries: 'china',
    countryCodes: 'chn',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'whole-pathogen vaccines',
    notes:
      'live-attenuated vaccine. plans for clinical trials in july. proof of concept testing done using mers-cov and various animal models.',
    numSites: '',
    otherPartners:
      'cepi,xiamen university,changchun-baike,hualan-bio,beijing wantai,sinovac,cnbg',
    phase: '',
    preferredName: 'delns1-sars-cov2-rbd laiv',
    productId: 15,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://fightcovid19.hku.hk/hku-state-key-laboratory-for-emerging-infectious-diseases-joins-global-effort-to-develop-covid-19-vaccine/',
      'https://www.hku.hk/press/news_detail_20788.html',
    ],
    sponsors: [
      {
        sponsorId: '6b014b07406a291e8e325b2a212ac65562a16644',
        sponsorName: 'University of Hong Kong',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: 'germany',
    countryCodes: 'deu',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes:
      'not named yet,2 products currently undergoing animal studies,plan to start a clinical trial in early summer',
    numSites: '',
    otherPartners: 'cepi',
    phase: '',
    preferredName: 'curevac_ag-16',
    productId: 16,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.curevac.com/our-pipeline',
      'https://www.curevac.com/news/curevac-focuses-on-the-development-of-mrna-based-coronavirus-vaccine-to-protect-people-worldwide',
      'https://www.youtube.com/watch?v=1zmwjjyok7a',
    ],
    sponsors: [
      {
        sponsorId: '40795cb229b892237d8be44830cd652481d40676',
        sponsorName: 'CureVac AG',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'unknown',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'ad5-ncov',
    conditionOrDisease: 'covid 19',
    countries: 'china',
    countryCodes: 'chn',
    currentStatus: 'phase 1',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'gene therapies',
    notes:
      'vaccine candidate is genetically engineered with the replication-defective adenovirus type 5 as the vector to express sars-cov-2 spike protein; immunogenic action; current study is assessing evaluate the safety,reactogenicity and immunogenicity; active but not recruiting',
    numSites: '1',
    otherPartners:
      'institute of biotechnology-academy of military medical sciences-pla of china,jiangsu province centers for disease control and prevention,hubei provincial center for disease control and prevention,tongji hospital',
    phase: '1',
    preferredName: 'ad5-ncov',
    productId: 17,
    productType: '',
    repurposed: 'new',
    siteLocations:
      'hubei provincial center for disease control and prevention - wuhan - hubei china',
    sources: [
      'https://clinicaltrials.gov/ct2/show/nct04313127?term=ad5-ncov&draw=2&rank=1',
      'https://www.bioworld.com/articles/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials  https://www.youtube.com/watch?v=1zmwjjyok7a',
    ],
    sponsors: [
      {
        sponsorId: 'ae6d6a42f1f04b04f866b7d03b344389efca16ee',
        sponsorName: 'CanSino Biologics Inc',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'discovery',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'unknown',
    notes:
      'using existing vaccine platform called gv-mva-vlp,3 candidates have been identified,animal trials soon to begin',
    numSites: '',
    otherPartners: 'bravovax',
    phase: '',
    preferredName: 'geovax_labs_inc-18',
    productId: 18,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.geovax.com/news/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program',
      'https://www.geovax.com/technology-pipeline/pipeline-summary',
    ],
    sponsors: [
      {
        sponsorId: 'f5413cebc2f1a8871f47600364147dc47dbb9ad1',
        sponsorName: 'GeoVax Labs Inc',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'unknown',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'ino-4700',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'ino-4700',
    productId: 19,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'a28cb988e230163b5e185750856269de4f3cd2eb',
        sponsorName: 'Inovio Pharmaceuticals Inc',
      },
      {
        sponsorId: 'a16b70b82bdd9b5e61c50e750862a8851ee80507',
        sponsorName: 'GeneOne Life Science',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'medicago-20',
    productId: 20,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'e59212c9eed9f476dcb441a9645267e5e6b915c2',
        sponsorName: 'Medicago',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'nasovax',
    chemicalName: 'nasovax analog (not currently specified)',
    conditionOrDisease: 'covid-19',
    countries: 'united sates',
    countryCodes: '',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes:
      'repurposing nasovax platform (recombinant intranasal delivery) for covid19 vaccine',
    numSites: '',
    otherPartners: 'altimmune',
    phase: '',
    preferredName: 'nasovax analog (not currently specified)',
    productId: 21,
    productType: '',
    repurposed: 'repurposed-approved',
    siteLocations: '',
    sources: [
      'https://www.precisionvaccinations.com/vaccines/nasovax-influenza-vaccine',
      'https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single',
    ],
    sponsors: [
      {
        sponsorId: 'e97fb449c577795bfb9ae1692146c17455a06ef8',
        sponsorName: 'Altimmune',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'unknown',
    trialId: '',
  },
  {
    brandName: 'ibv',
    chemicalName: 'avian coronavirus infectious bronchitis virus (ibv) vaccine',
    conditionOrDisease: '',
    countries: 'israel',
    countryCodes: 'isr',
    currentStatus: 'phase 1',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'whole-pathogen vaccines',
    notes:
      'adaption of avian coronavirus infectious bronchitis virus vaccine for human use',
    numSites: '',
    otherPartners:
      'israel innovation authority,health ministry and the headquarters of the national digital israel initiative',
    phase: '',
    preferredName:
      'avian coronavirus infectious bronchitis virus (ibv) vaccine',
    productId: 22,
    productType: '',
    repurposed: 'repurposed-not approved',
    siteLocations: '',
    sources: [
      'https://www.trialsitenews.com/israel-government-announces-13m-covid-19-research-funds-while-migals-claims-a-covid-19-breakthrough/',
    ],
    sponsors: [
      {
        sponsorId: '83dd887c3fd8789867722d2edd6b259ee645f1a3',
        sponsorName: 'MIGAL Research Institute',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'unknown',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'tnx-1800',
    conditionOrDisease: '',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'discovery',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'tnx-1800',
    productId: 23,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: ['https://www.tonixpharma.com/'],
    sponsors: [
      {
        sponsorId: '40e82256fff7abb570316aa4f46cf693fc0c6c98',
        sponsorName: 'Tonix Pharmaceuticals',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 's-trimer',
    chemicalName: 'recombinant subunit vaccine',
    conditionOrDisease: '',
    countries: 'china',
    countryCodes: 'chn',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes: '',
    numSites: '',
    otherPartners: 'glaxosmithkline',
    phase: '',
    preferredName: 'recombinant subunit vaccine',
    productId: 24,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.bioworld.com/articles/433055-clover-produces-subunit-vaccine-candidate-s-trimer-for-coronavirus',
      'https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1',
    ],
    sponsors: [
      {
        sponsorId: '2ad3e27aa56a9275005c084d1c2ca3c71cc945a1',
        sponsorName: 'Clover Biopharmaceuticals',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'linear dna vaccine',
    conditionOrDisease: '',
    countries: 'united states,rome - italy',
    countryCodes: '',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes: 'pcr produced linear dna vaccine',
    numSites: '',
    otherPartners: 'applied dna sciences,takis biotech',
    phase: '',
    preferredName: 'linear dna vaccine',
    productId: 25,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://adnas.com/coronavirus-preclinical-trials-italy-ministry-health/',
    ],
    sponsors: [
      {
        sponsorId: '35a1314de34e0181bb072a8ab28865c9f1cdecc1',
        sponsorName: 'Applied DNA Sciences',
      },
      {
        sponsorId: '3d80bed6c0a0fd89072a0112ae97d02303dc1b5e',
        sponsorName: 'Takis Biotech',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: 'nanoflu',
    chemicalName: '',
    conditionOrDisease: 'seasonal flu/influenza',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'manufacturing',
    indication: 'other',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'subunit vaccines',
    notes:
      'recombinant quadrivalent seasonal influenza vaccine using hemagglutinin (ha) protein nanoparticles',
    numSites: '19',
    otherPartners: 'novavax,emergent biosolutions inc,cepi',
    phase: '3',
    preferredName: 'nanoflu',
    productId: 26,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'http://ir.novavax.com/news-releases/news-release-details/novavax-nanoflu-achieves-all-primary-endpoints-phase-3-clinical',
    ],
    sponsors: [
      {
        sponsorId: 'b83afd40b4f01cc1236b6df8d6a2476e04cb0bac',
        sponsorName: 'Novavax',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'predictive_oncology-27',
    productId: 27,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '5e5fd3a94173dbc6792d6963099af3d35fffc59a',
        sponsorName: 'Predictive Oncology',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'integral_molecular-28',
    productId: 28,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '2430ef62933375e356e074b24398ccb1c52d48af',
        sponsorName: 'Integral Molecular',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: 'discovery',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes: 'using modern antigen technology',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'aj_vaccines-29',
    productId: 29,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: ['https://ajvaccines.com/news/'],
    sponsors: [
      {
        sponsorId: 'f3d84a99a68fdd7ad327bbc8ce41458fc29dec50',
        sponsorName: 'AJ Vaccines',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'remdesivir',
    conditionOrDisease: 'covid 19',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'phase 3',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'small molecule',
    notes:
      'other trials undertaken by niad-usa,inserm-france,china japanese friendship hospital,no of study is increasing rapidly',
    numSites: '41',
    otherPartners: 'gilead sciences',
    phase: '3',
    preferredName: 'remdesivir',
    productId: 30,
    productType: '',
    repurposed: 'repurposed-not approved',
    siteLocations:
      'kaiser permanente los angeles medical center - los angeles - california; hoag memorial hospital presbyterian - newport beach - california; stanford hospital - stanford - california; university of chicago - chicago - illinois; brigham & women\'s hospital and harvard medical school - boston - massachusets; center for virology and vaccine research,beth israel deaconess medical center - lagrangeville - new york; jamaica hospital medical center - jamaica - new york; danbury hospital - lagrangeville - new york; providence portland medical center - portland - oregon; providence st. vincent medical center - portland - oregon; the miriam hospital - providence - rhode island; baylor university medical center - dallas - texas; houston methodist hospital - houston - texas; providence medical research center - everett - washington;  swedish center for comprehensive care - seattle - washington; multicare tacoma general hospital - tacoma - washington; klinikum rechts der isar der tu munchen,klinik und poliklinik innere medizin 2 - munich - germany; prince of wales hospital - hong kong - hong kong; princess margaret hospital - hong kong - hong kong; queen mary hospital - hong kong - hong kong; azienda ospedaliero universitaria di parma - parma - islamic republic of iran; asst degli spedali civili di brescia - brescia - italy; asst di cremona - azienda socio sanitaria territor - cremona - italy; asst fatebenefratelli sacco - milano - italy; uoc malattie infettive e tropicali,azienda ospedaliera di padova - padova pd - italy;  malattie infettive i,fondazione irccs policlinico san matteo - pavia - italy; kyungpook national university hospital - daegu - republic of korea; seoul medical center - seoul - republic of korea; national medical center - seoul - korea; national university hospital - singapore - singapore; singapore general hospital - singapore - singapore; national centre for infectious diseases - tan tock seng hospital - singapore - singapore; hospital clinic de barcelona - barcelona - spain; hospital universitario cruces - bizakaia - spain; hospital universitario la paz - madrid - spain; hopitaux universitaires de gen\u00e8ve - gen\u00e8ve 14 - switzerland; ospedale regionale di locarno la carit\u00e0 - lugano - switzerland; universit\u00e4tsspital z\u00fcrich - z\u00fcrich - switzerland; kaohsiung veterans general hospital - kaohsiung - taiwan; china medical university hospital- taichung - taiwan; national taiwan university hospital - taipei city -taiwan',
    sources: [
      'https://www.gilead.com/purpose/advancing-global-health/covid-19',
      'https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials',
      'https://clinicaltrials.gov/ct2/show/nct04292730',
    ],
    sponsors: [
      {
        sponsorId: 'cbb34f9aed92e21ff89501b842a385faabf9c8c6',
        sponsorName: 'Gilead Sciences Inc',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs-not specified',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'mabvrilmumab',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'mabvrilmumab',
    productId: 116,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'f0b7d34b0d2bf183e3127d2f2ae6859f2e0c2303',
        sponsorName: 'Kiniksa Pharmaceuticals',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'vir_generation_bio-117',
    productId: 117,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'dc00d3517e3f13a2cb70d81bbab7f9d0514888f3',
        sponsorName: 'Vir',
      },
      {
        sponsorId: 'bcfff0dfda52208b330d28e46746495f992fcded',
        sponsorName: 'Generation Bio',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'vir_wuxi_biologics-118',
    productId: 118,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'dc00d3517e3f13a2cb70d81bbab7f9d0514888f3',
        sponsorName: 'Vir',
      },
      {
        sponsorId: '93b3b8946f754bf8d8937c425327d7e3188585ac',
        sponsorName: 'WuXi Biologics',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'vir_xencor-119',
    productId: 119,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'dc00d3517e3f13a2cb70d81bbab7f9d0514888f3',
        sponsorName: 'Vir',
      },
      {
        sponsorId: 'e2d696e69bf7af5a9d75dc0e458af621a10d78ba',
        sponsorName: 'Xencor',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'alnylam_vir-120',
    productId: 120,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '2a0f6fec0d49bd2ca117ccbc0cfd8c816f776165',
        sponsorName: 'Alnylam',
      },
      {
        sponsorId: 'dc00d3517e3f13a2cb70d81bbab7f9d0514888f3',
        sponsorName: 'Vir',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'plasma immunoglobulins',
    chemicalName: 'tak-888',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'tak888',
    productId: 121,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '31759effba9dd9037b4a5b2a4e1bf87cb0e4042b',
        sponsorName: 'Takeda',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'kaletra,aluvia',
    chemicalName: 'lopinavir,ritonavir',
    conditionOrDisease: '2019-ncov',
    countries: 'multiple',
    countryCodes: '',
    currentStatus: '?phase 4',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'small molecule',
    notes:
      'unclear what to do with this one - abbvie is not the sponsor but is the manufacturer of the drug. some studies are published: https://www.nejm.org/doi/pdf/10.1056/nejmoa2001282?articletools=true,https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1.full.pdf. note that for the highest study there were multiple phase 4 so i picked the largest one that had alrady started recruiting',
    numSites: '1',
    otherPartners: 'abbvie',
    phase: '4',
    preferredName: 'lopinavir,ritonavir',
    productId: 31,
    productType: '',
    repurposed: 'repurposed-approved',
    siteLocations: 'wuhan - china',
    sources: [
      'https://milkeninstitute.org/sites/default/files/2020-03/covid19%20tracker%20new3-30-20.pdf',
      'https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/pdfs/factsheet-coronavirus-030420.pdf',
      'https://www.nejm.org/doi/pdf/10.1056/nejmoa2001282?articletools=true',
      'https://www.drugbank.ca/drugs/db01601; https://www.drugbank.ca/drugs/db01601',
      'https://www.kaletra.com/',
      'https://www.clinicaltrials.gov/ct2/show/nct04255017?term=lopinavir+ritonavir&cond=coronavirus+or+corona+or+covid+or+sars+or+acute+respiratory+or+ards+or+pneumonia&phase=3&draw=2&rank=2',
    ],
    sponsors: [
      {
        sponsorId: '69e116d4f9df799550df0e74438d37589994fb45',
        sponsorName: 'AbbVie',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs-antiretrovirals',
    trialId: '',
  },
  {
    brandName: 'kevzara',
    chemicalName: 'sarilumab',
    conditionOrDisease: 'covid-19',
    countries: 'unites states',
    countryCodes: '',
    currentStatus: 'phase 3',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes: '',
    numSites: '57',
    otherPartners: '',
    phase: '3',
    preferredName: 'sarilumab',
    productId: 32,
    productType: '',
    repurposed: 'repurposed-approved',
    siteLocations: 'if anyone else has done,copy accross',
    sources: [
      'https://www.drugbank.ca/drugs/db11767',
      'http://www.news.sanofi.us/2020-03-16-sanofi-and-regeneron-begin-global-kevzara-r-sarilumab-clinical-trial-program-in-patients-with-severe-covid-19',
      'https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-begin-global-kevzarar-sarilumab-clinical',
      'https://www.google.com/search?rlz=1c5chfa_engb854gb854&sxsrf=alekk022og2hfqxgb2ognk6vdmns2vrrhq%3a1585861871624&ei=71sgxutzjykvggfajrv4ba&q=regeneron+&oq=regeneron+&gs_lcp=cgzwc3ktywiqaziicaaqgweqkqiybagaeemybqgaeimbmguiabcdatifcaaqgweybqgaeimbmgiiadiccaaybqgaeimbmguiabcdatoecaaqrzoeccmqjzofcaaqkqi6bwgaebqqhwjq2u1y2ltgp1xoahabeacaayybiagsb5ibazyum5gbakabaaobb2d3cy13axo&sclient=psy-ab&ved=0ahukewikjzxs08roahwcl-akhudhdk8q4dudcas&uact=5',
      'https://clinicaltrials.gov/ct2/show/nct04315298?term=kevzara&cond=coronavirus+or+corona+or+covid+or+sars+or+acute+respiratory+or+ards+or+pneumonia&draw=2',
      'https://clinicaltrials.gov/ct2/show/nct04315298?term=kevzara&cond=coronavirus+or+corona+or+covid+or+sars+or+acute+respiratory+or+ards+or+pneumonia&draw=2&rank=1',
      'https://www.clinicaltrials.gov/ct2/show/nct04315298',
    ],
    sponsors: [
      {
        sponsorId: 'a7cbf979a98fdc448b32b211e3d5e8264875995e',
        sponsorName: 'Regeneron',
      },
      {
        sponsorId: '551135a9f6ade78853bbd5fdbd66283c70e2f776',
        sponsorName: 'Sanofi',
      },
    ],
    status: 'ongoing',
    therapeuticApproach:
      'nonspecific anti-inflammatory and immunosuppressive drugs',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'hydroxychloroquine',
    conditionOrDisease: 'covid 19',
    countries: 'na',
    countryCodes: 'nam',
    currentStatus: '?phase 4',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: 'small molecule',
    notes: '',
    numSites: 'not listed',
    otherPartners: '',
    phase: '4',
    preferredName: 'hydroxychloroquine',
    productId: 33,
    productType: '',
    repurposed: 'repurposed-approved',
    siteLocations: 'not listed',
    sources: [
      'https://milkeninstitute.org/sites/default/files/2020-03/covid19%20tracker%20new3-30-20.pdf',
      'https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html; https://www.npr.org/sections/coronavirus-live-updates/2020/03/31/824572119/clinical-trials-set-to-determine-if-anti-malaria-drug-effective-against-covid-19',
      'https://www.drugbank.ca/drugs/db01611',
      'https://www.drugbank.ca/drugs/db01612',
      'https://www.drugbank.ca/drugs/db01613',
      'https://www.clinicaltrials.gov/ct2/show/nct04330495?term=hydroxychloroquine&cond=coronavirus+or+corona+or+covid+or+sars+or+acute+respiratory+or+ards+or+pneumonia&phase=3&draw=2&rank=2',
      'https://www.clinicaltrials.gov/ct2/show/nct04330495?term=hydroxychloroquine&cond=coronavirus+or+corona+or+covid+or+sars+or+acute+respiratory+or+ards+or+pneumonia&phase=3&draw=2&rank=3',
      'https://www.clinicaltrials.gov/ct2/show/nct04330495?term=hydroxychloroquine&cond=coronavirus+or+corona+or+covid+or+sars+or+acute+respiratory+or+ards+or+pneumonia&phase=3&draw=2&rank=4',
      'https://www.clinicaltrials.gov/ct2/show/nct04330495?term=hydroxychloroquine&cond=coronavirus+or+corona+or+covid+or+sars+or+acute+respiratory+or+ards+or+pneumonia&phase=3&draw=2&rank=5',
      'https://www.clinicaltrials.gov/ct2/show/nct04330495?term=hydroxychloroquine&cond=coronavirus+or+corona+or+covid+or+sars+or+acute+respiratory+or+ards+or+pneumonia&phase=3&draw=2&rank=6',
      'https://www.clinicaltrials.gov/ct2/show/nct04330495?term=hydroxychloroquine&cond=coronavirus+or+corona+or+covid+or+sars+or+acute+respiratory+or+ards+or+pneumonia&phase=3&draw=2&rank=7',
      'https://www.clinicaltrials.gov/ct2/show/nct04330495?term=hydroxychloroquine&cond=coronavirus+or+corona+or+covid+or+sars+or+acute+respiratory+or+ards+or+pneumonia&phase=3&draw=2&rank=8',
      'https://www.clinicaltrials.gov/ct2/show/nct04330495?term=hydroxychloroquine&cond=coronavirus+or+corona+or+covid+or+sars+or+acute+respiratory+or+ards+or+pneumonia&phase=3&draw=2&rank=9',
      'https://www.clinicaltrials.gov/ct2/show/nct04330495?term=hydroxychloroquine&cond=coronavirus+or+corona+or+covid+or+sars+or+acute+respiratory+or+ards+or+pneumonia&phase=3&draw=2&rank=10',
      'https://www.clinicaltrials.gov/ct2/show/nct04330495?term=hydroxychloroquine&cond=coronavirus+or+corona+or+covid+or+sars+or+acute+respiratory+or+ards+or+pneumonia&phase=3&draw=2&rank=11',
    ],
    sponsors: [
      {
        sponsorId: '5834c4dd71c724c9e835c161ccf536281d7a86d1',
        sponsorName: 'Numerous University of Minnesota',
      },
      {
        sponsorId: '38652628acf1b84b92cad2bea1a82015a920b0c3',
        sponsorName: 'University of Oxford',
      },
      {
        sponsorId: 'ff8a0c54a353095e074101e6dc11d7f2a8f67131',
        sponsorName: 'IHUM\u00e9diterran\u00e9e Infection and others',
      },
      {
        sponsorId: '522fd3e933198af94a37b777133a90e18fe25698',
        sponsorName: 'World Health Organization SOLIDARITY trial chloroquine',
      },
      {
        sponsorId: 'b552938f2dfa5e64010355ac8e2b30bc0e7ed4cc',
        sponsorName:
          'New York State Department of Health hydroxychloroquine with zithromax',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antimalarial drugs',
    trialId: '',
  },
  {
    brandName: 'tjm2',
    chemicalName: 'tj003234',
    conditionOrDisease: '',
    countries: 'china',
    countryCodes: 'chn',
    currentStatus: 'phase 1',
    indication: 'ards',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes:
      'antibody against gm-csf. previously passed a phase 1 trial. inds submitted for phase ii clinical trials in china usa and south korea.',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'tj003234',
    productId: 35,
    productType: '',
    repurposed: 'repurposed-not approved',
    siteLocations: '',
    sources: [
      'http://www.i-mabbiopharma.com/en/article-491.aspx',
      'https://clinicaltrials.gov/ct2/show/nct03794180',
      'https://apnews.com/globe%20newswire/bd107410eacfaa7143eb9ec954e11c70',
    ],
    sponsors: [
      {
        sponsorId: '4d5fc82efed329adf6897a54f395828e900a3a4d',
        sponsorName: 'IMab Biopharma',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'monoclonal antibodies',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'at-100',
    conditionOrDisease: '',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes:
      'recombinant surfactant protein developed to treat bronchopulmonary dysplatia. no timeline for clinical trials.',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'at-100',
    productId: 36,
    productType: '',
    repurposed: 'repurposed-not approved',
    siteLocations: '',
    sources: [
      'https://www.airwaytherapeutics.com/at-100/',
      'https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/',
    ],
    sponsors: [
      {
        sponsorId: 'cce5891ec7c3582e4abbb8a5a1675065288b051b',
        sponsorName: 'Airway Therapeutics',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'tzls-501',
    conditionOrDisease: '',
    countries: 'united kingdom',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes: '',
    numSites: '',
    otherPartners: 'tiziana life sciences,novimmune',
    phase: '',
    preferredName: 'tzls-501',
    productId: 37,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.marketwatch.com/story/uk-biotech-tiziana-life-sciences-says-its-tzls-501-may-be-of-use-in-treating-coronavirus-2020-03-11',
    ],
    sponsors: [
      {
        sponsorId: '2a18b405cfddff30dc89c827294ce141e1078ed6',
        sponsorName: 'Tiziana Life Sciences',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'oya1',
    conditionOrDisease: '',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'small molecule',
    notes: '',
    numSites: '',
    otherPartners: 'oyagen',
    phase: '',
    preferredName: 'oya1',
    productId: 38,
    productType: '',
    repurposed: 'repurposed-not approved',
    siteLocations: '',
    sources: [
      'https://www.biospace.com/article/releases/oyagen-inc-announces-a-compound-in-development-with-broad-antiviral-activity-against-coronaviruses-including-sars-cov-2/',
    ],
    sponsors: [
      {
        sponsorId: '09c1011fb00f7f2c97e9b4ebc1373e23f10f3703',
        sponsorName: 'OyaGen',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs-broad spectrum',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'bpi-002',
    conditionOrDisease: '',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'small molecule',
    notes:
      'also being considered as a vaccine adjuvant to stimulate long term immunity,very little information is available on development stages - a patent has been filed for it by the company but it is not clear what that translates to,information in column t was seen on just one website',
    numSites: '',
    otherPartners: 'beyondspring inc',
    phase: '',
    preferredName: 'bpi-002',
    productId: 39,
    productType: '',
    repurposed: 'repurposed-not approved',
    siteLocations: '',
    sources: [
      'https://www.biospace.com/article/releases/beyondspring-files-for-patent-protection-on-bpi-002-for-the-treatment-of-viral-infections-including-covid-19/',
      'https://www.beyondspringpharma.com/otherpipeline/index.aspx',
      'https://adisinsight.springer.com/drugs/800049541',
      'https://www.beyondspringpharma.com/pipelineoverview/index.aspx',
    ],
    sponsors: [
      {
        sponsorId: 'bdc58d6b3c51adacec8fd2e5f71d1d5d71046d8d',
        sponsorName: 'BeyondSpring Inc',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs-broad spectrum',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'np-120 (ifenprodil)',
    conditionOrDisease: 'idiopathic pulmonary fibrosis',
    countries: 'canada',
    countryCodes: 'can',
    currentStatus: 'phase 2',
    indication: 'ards',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes:
      'therapeutic approach - receptor antagonist,drug originally evaluated for treatment of idiopathic pulmonary fibrosis',
    numSites: '',
    otherPartners: 'cascade chemistry',
    phase: '2',
    preferredName: 'np-120 (ifenprodil)',
    productId: 40,
    productType: '',
    repurposed: 'repurposed-not approved',
    siteLocations: '',
    sources: [
      'https://algernonpharmaceuticals.com/ipf-np-120/',
      'https://clinicaltrials.gov/ct2/show/nct04318704?term=ifenprodil&draw=2&rank=2',
    ],
    sponsors: [
      {
        sponsorId: '4ec6ff9fa7840783f9d6a9a99ce82cc52a732239',
        sponsorName: 'Algernon Pharmaceuticals',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'apn01',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'apn01',
    productId: 41,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '6f60b15593583caa5a157b68e379e898ed540bfe',
        sponsorName: 'University of British Columbia',
      },
      {
        sponsorId: '135275cdf7dd39808bf7b9ddb4115db4750d3cdc',
        sponsorName: 'APEIRON Biologics',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'brilacidin',
    chemicalName: 'brilacidin tetrahydrochloride',
    conditionOrDisease: '',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'small molecule',
    notes: '',
    numSites: '',
    otherPartners: 'innovation pharamaceuticals',
    phase: '',
    preferredName: 'brilacidin tetrahydrochloride',
    productId: 42,
    productType: '',
    repurposed: 'repurposed-not approved',
    siteLocations: '',
    sources: [
      'https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e5c0bbea72c2f71ab0978ee/1583090668780/ipix+brilacidin+defensin+mimetics+-+covid-19+overview+march+1+2020+update.pdf',
    ],
    sponsors: [
      {
        sponsorId: 'd74b3bc88aff79062ddc7572f048d10a2f1b7254',
        sponsorName: 'Innovation Pharmaceuticals',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antibiotics and antiparasitics',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'leronlimab',
    conditionOrDisease: '',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'phase 2',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes:
      'patient treatment underway via emergency ind,phase 2 trial protocol filed',
    numSites: '',
    otherPartners: 'redchip companies',
    phase: '',
    preferredName: 'leronlimab',
    productId: 43,
    productType: '',
    repurposed: 'repurposed-approved',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'a5c509d28e5944d0d7121691e82a49f47e20f7ef',
        sponsorName: 'CytoDyn',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'monoclonal antibodies',
    trialId: '',
  },
  {
    brandName: 'btx-025',
    chemicalName: 'novel viral inhibitor',
    conditionOrDisease: '',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'discovery',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'small molecule',
    notes:
      'novel galectin inhibitor for use in covid-19. currently pre-clinical.',
    numSites: '',
    otherPartners: 'bioxytran',
    phase: '',
    preferredName: 'novel viral inhibitor',
    productId: 44,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.globenewswire.com/news-release/2020/03/24/2005534/0/en/bioxytran-licenses-novel-viral-inhibitor-for-covid-19-patients.html',
    ],
    sponsors: [
      {
        sponsorId: '6e5983b2fe019c343dfaeb0ad2e7419f3dfaa118',
        sponsorName: 'BIOXYTRAN',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs-not specified',
    trialId: '',
  },
  {
    brandName: 'plasma immunoglobulins',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'plasma_immunoglobulins',
    productId: 122,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '1c0e0b84ff56e26451831dfaf21673eee50a8634',
        sponsorName: 'CERS',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'plasma immunoglobulins',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'plasma_immunoglobulins',
    productId: 123,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '893c4bdb7386d6aa83dda414cb161d199a4e191f',
        sponsorName: 'Grifols',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'plasma immunoglobulins',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'plasma_immunoglobulins',
    productId: 124,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '67cc1b58cfec53c29d2af191d961276e32239c1b',
        sponsorName: 'Mount Sinai Health System',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'plasma immunoglobulins',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'plasma_immunoglobulins',
    productId: 125,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'de649c1e3ec322020be03d52590a6461de6d1a6a',
        sponsorName: 'China National Biotec',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'neurrx_relief_therapeutics-126',
    productId: 126,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '8c18a287de447a9a8dfa13df486ebd28237a8878',
        sponsorName: 'NeurRx',
      },
      {
        sponsorId: 'a30d64bea24fb02aa2230fa1359a99643a0fc3a3',
        sponsorName: 'Relief Therapeutics',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'actemra',
    conditionOrDisease: 'severe covid-19 pneumonia',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'phase 3',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes:
      'first approved anti-il-6 receptor biologic available in both intravenous (iv) and subcutaneous (sc) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (ra).',
    numSites: 'not disclosed',
    otherPartners: 'roche',
    phase: '3',
    preferredName: 'actemra',
    productId: 45,
    productType: '',
    repurposed: 'repurposed-not approved',
    siteLocations: 'global',
    sources: ['https://www.roche.com/media/releases/med-cor-2020-03-19.htm'],
    sponsors: [
      {
        sponsorId: '7acdde062bf6d75cd4f60fb9c8d60bb3caa89d9a',
        sponsorName: 'Roche',
      },
    ],
    status: 'ongoing',
    therapeuticApproach:
      'nonspecific anti-inflammatory and immunosuppressive drugs',
    trialId: '',
  },
  {
    brandName: 'galidesivir',
    chemicalName: 'bcx4430',
    conditionOrDisease: 'yellow fever',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'phase 2',
    indication: 'other',
    interventionType: 'therapeutic',
    moleculeType: 'small molecule',
    notes: 'neucleoside analogue for yellow fever,broad spectrum.',
    numSites: 'not disclosed',
    otherPartners: 'niaid,barda-nih',
    phase: '1',
    preferredName: 'bcx4430',
    productId: 46,
    productType: '',
    repurposed: 'new',
    siteLocations: 'not disclosed',
    sources: [
      'http://ir.biocryst.com/news-releases/news-release-details/biocryst-completes-phase-1-clinical-trial-galidesivir',
    ],
    sponsors: [
      {
        sponsorId: '0b4eda6dd2c2599e8ad9c5c9117893d90ae570f4',
        sponsorName: 'Biocryst Pharma',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs-broad spectrum',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'regn3048-3051',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'regn3048-3051',
    productId: 47,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'a7cbf979a98fdc448b32b211e3d5e8264875995e',
        sponsorName: 'Regeneron',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'sng001',
    conditionOrDisease: 'covid-19',
    countries: 'united kingdom',
    countryCodes: 'gbr',
    currentStatus: 'phase 2',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'other',
    notes: 'inhaled forumation of beta-1a interferon',
    numSites: '20',
    otherPartners: 'public funding through shares',
    phase: '2',
    preferredName: 'sng001',
    productId: 48,
    productType: '',
    repurposed: 'repurposed-approved',
    siteLocations: 'uk',
    sources: [
      'https://www.synairgen.com/covid-19/',
      'https://www.morningstar.co.uk/uk/news/an_1585205934091906300/synairgen-raises-cash-to-go-towards-covid-19-drug-trial.aspx',
      'https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/gb',
      'https://www.clinicaltrialsarena.com/news/cansino-synairgen-covid-19-trials/',
    ],
    sponsors: [
      {
        sponsorId: '844645398c47a20691e7b88009bf4a28ca9e0a56',
        sponsorName: 'Synairgen Research',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'amnioboost',
    conditionOrDisease: 'covid-19',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'phase 1',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'other',
    notes: '',
    numSites: '1',
    otherPartners: 'lattice biologics',
    phase: '1',
    preferredName: 'amnioboost',
    productId: 49,
    productType: '',
    repurposed: 'repurposed-approved',
    siteLocations: 'seattle,usa',
    sources: [
      'https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/',
      'https://www.businesswire.com/news/home/20200317005218/en/lattice-biologics-ltd.-announces-initial-recruitment-patients',
    ],
    sponsors: [
      {
        sponsorId: '3269ba5b3b1fa17511555e6336cff3ddd90b84b2',
        sponsorName: 'Lattice Biologics',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'discovery',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'unknown',
    notes: 'direct acting antiviral',
    numSites: '',
    otherPartners: 'enanta pharmaceuticals',
    phase: '',
    preferredName: 'enanta_pharmaceuticals-50',
    productId: 50,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.enanta.com/investors/news-releases/press-release/2020/enanta-pharmaceuticals-announces-efforts-to-discover-a-treatment-for-the-novel-coronavirus-disease-covid-19/default.aspx',
    ],
    sponsors: [
      {
        sponsorId: '7bf6d2f389a2e6a86e1d696dcc1c2052ef9a9eae',
        sponsorName: 'Enanta Pharmaceuticals',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs-not specified',
    trialId: '',
  },
  {
    brandName: 'vaxart',
    chemicalName: 'vaast',
    conditionOrDisease: 'covid-19',
    countries: 'usa',
    countryCodes: 'usa',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'recombinant vaccines',
    notes:
      'oral vaccine,recombinant adenovirus expressing ha,non-replicating viral vector',
    numSites: '',
    otherPartners: 'emergent biosolutions,vaxart',
    phase: '1',
    preferredName: 'vaast',
    productId: 51,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'cd5be69c518689ef12547e8559a4ff1c7ebed1d1',
        sponsorName: 'Emergent BioSolutions',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'other antiviral drugs',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'leaps covid-19',
    conditionOrDisease: 'covid-19',
    countries: 'usa',
    countryCodes: 'usa',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes: 'immunotherapy',
    numSites: '',
    otherPartners:
      'cel-sci,university of georgia\u2019s (uga\u2019s) center for vaccines',
    phase: '1',
    preferredName: 'leaps covid-19',
    productId: 52,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '7146a8671f847f80a0c4c99c0466916089840d58',
        sponsorName: 'CELSCI',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs-broad spectrum',
    trialId: '',
  },
  {
    brandName: 'tak-888',
    chemicalName: 'anti-sars-cov-2 polyclonal hyperimmune globulin (h-ig)',
    conditionOrDisease: 'covid-19',
    countries: 'japan',
    countryCodes: 'jpn',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes: 'a plasma-derived therapy',
    numSites: '',
    otherPartners: 'takeda pharmaceutical company',
    phase: '1',
    preferredName: 'anti-sars-cov-2 polyclonal hyperimmune globulin (h-ig)',
    productId: 53,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'ab95e09c1c41756dc8b947ebd1fa0e087a23da6c',
        sponsorName: 'Takeda Pharmaceutical Company',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs-broad spectrum',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'azithromycin-hydroxychloroquine combination',
    conditionOrDisease: '',
    countries: 'usa',
    countryCodes: 'usa',
    currentStatus: 'discovery',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'other',
    notes: '',
    numSites: '',
    otherPartners: 'pfizer',
    phase: '',
    preferredName: 'azithromycin-hydroxychloroquine combination',
    productId: 54,
    productType: '',
    repurposed: 'repurposed-not approved',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '531d5b28f1f18f219741627c0f2a1e09d355e46a',
        sponsorName: 'Pfizer',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antibiotics and antiparasitics',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'ot-101',
    conditionOrDisease: '',
    countries: 'united states',
    countryCodes: 'usa',
    currentStatus: 'phase 3',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein based',
    notes: 'used to treat covid-19 induced pneumonia',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'ot-101',
    productId: 55,
    productType: '',
    repurposed: 'repurposed',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '839146f1d67c1b00a841adde72a3555186ed2ee2',
        sponsorName: 'Mateon Therapeutics',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs- broad spectrum',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'remdesivir',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'small molecule',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'remdesivir',
    productId: 56,
    productType: '',
    repurposed: 'repurposed',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '597be3ec42623eb2b339b165717d84c7c3137601',
        sponsorName: 'Columbia University',
      },
    ],
    status: '',
    therapeuticApproach: 'antiviral- not specified',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'southwest_research_institute-57',
    productId: 57,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '24d9d6c7cef2fb07a9bf63de1e32e0d49e73466f',
        sponsorName: 'Southwest Research Institute',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'nanoviricides-58',
    productId: 58,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'ce9215688edb9650cbc3b3d92876af43dd53d52b',
        sponsorName: 'NanoViricides',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'modified anti-sars-cov-2 antibodies',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'prophylactic/therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes:
      '2 different modifications of one single clone of antibody originally developed against sars-cov-1,shown to act as both vaccine and therapeutic',
    numSites: '',
    otherPartners: 'wuxi biologics,biogen',
    phase: '',
    preferredName: 'modified anti-sars-cov-2 antibodies',
    productId: 59,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/',
      'https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer; https://www.biospace.com/article/vir-biotechnology-ids-2-monoclonal-antibodies-against-the-covid-19-coronavirus/',
      'https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer',
    ],
    sponsors: [
      {
        sponsorId: 'ec6e5f3e381b52ffa801d3826f90ffc80615c431',
        sponsorName: 'Vir Biotechnology',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'monoclonal antibodies',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'sirna against  sars-cov-1/2',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes: '350 candidates undergoing in vitro test',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'sirna against  sars-cov-1/2',
    productId: 60,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: ['https://investors.alnylam.com/press-release?id=24656'],
    sponsors: [
      {
        sponsorId: '2a0f6fec0d49bd2ca117ccbc0cfd8c816f776165',
        sponsorName: 'Alnylam',
      },
      {
        sponsorId: 'ec6e5f3e381b52ffa801d3826f90ffc80615c431',
        sponsorName: 'Vir Biotechnology',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs-antiretrovirals',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'sirna against  sars-cov-2',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'nucleic acid based therapies/vaccines',
    notes: '150 candidates under in vitro test',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'sirna against  sars-cov-2',
    productId: 61,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/',
      'https://www.npr.org/sections/health-shots/2020/02/19/807338329/hunt-for-new-coronavirus-treatments-includes-gene-silencing-and-monoclonal-antib',
    ],
    sponsors: [
      {
        sponsorId: 'd4d4713f1054b2bc9d367a86155cb363519d5ad5',
        sponsorName: 'Sirnaomics',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs-antiretrovirals',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: 'canada',
    countryCodes: 'can',
    currentStatus: 'discovery',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes: 'monoclonal antibodies,500 antibody sequences isolated 03/12/2020',
    numSites: '',
    otherPartners: 'vaccine research centre - niaid',
    phase: '',
    preferredName: 'abcellera_biologics_eli_lilly_and_company-63',
    productId: 63,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.genengnews.com/news/to-develop-coronavirus-treatment-lilly-taps-abcellera-antibody-platform/',
    ],
    sponsors: [
      {
        sponsorId: 'c3e548eb19a8c76ea5f8eeabdbc8086a91e469af',
        sponsorName: 'AbCellera Biologics',
      },
      {
        sponsorId: '3415f73b4bae4701d6612a2aa318423dc3c571b2',
        sponsorName: 'Eli Lilly and Company',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'monoclonal antibodies',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'bdb-001',
    conditionOrDisease: 'covid-19',
    countries: 'china',
    countryCodes: 'chn',
    currentStatus: 'phase 2',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes: 'anti-c5a antibody,phase 2 trial number 2020l0003',
    numSites: '',
    otherPartners: 'staidson (beijing) biopharmaceuticals co. ltd,inflarx',
    phase: '2',
    preferredName: 'bdb-001',
    productId: 64,
    productType: '',
    repurposed: 'repurposed-not approved',
    siteLocations: '',
    sources: [
      'https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/',
      'https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1.full.pdf',
      'https://www.bioworld.com/articles/433447-increasing-number-of-biopharma-drugs-target-covid-19-as-virus-spreads',
      'https://www.staidson.com/article/147.html',
      'https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1',
    ],
    sponsors: [
      {
        sponsorId: 'ff5ce7f46efeff43870c4a88459cedf1e13cc9c1',
        sponsorName: 'Beijing Defengrei Biotechnology',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'monoclonal antibodies',
    trialId: '',
  },
  {
    brandName: 'sylvant',
    chemicalName: 'siltuximab',
    conditionOrDisease: 'covid-19',
    countries: 'england',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes: 'clinical trial nct04322188 started but phase unknown',
    numSites: '1',
    otherPartners: 'ergomed',
    phase: 'unknown',
    preferredName: 'siltuximab',
    productId: 65,
    productType: '',
    repurposed: 'repurposed-approved',
    siteLocations: 'papa giovanni xxiii hospital - italy',
    sources: [
      'https://www.clinicaltrialsarena.com/news/eusa-pharma-siltuximab-study-covid-19/',
      'https://www.clinicaltrials.gov/ct2/show/record/nct04322188',
    ],
    sponsors: [
      {
        sponsorId: '887084fb166ace787dba446286c132705fbea1b3',
        sponsorName: 'EUSA Pharma',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'monoclonal antibodies',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '47d11',
    conditionOrDisease: '',
    countries: 'china',
    countryCodes: 'chn',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes: 'monoclonal antibodies',
    numSites: '',
    otherPartners: 'mount sinai,utrecht university,eurasmus mc',
    phase: '',
    preferredName: '47d11',
    productId: 66,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.biorxiv.org/content/10.1101/2020.03.11.987958v1.full.pdf+html',
    ],
    sponsors: [
      {
        sponsorId: '4e2f58ce0e723737336ad8f95d829829f4eca5cd',
        sponsorName: 'Harbour Biomed',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'monoclonal antibodies',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'sti-4398',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'sti4398',
    productId: 127,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'dd736e19d9cf47b8b0d9049c8729f5f8c706b691',
        sponsorName: 'Sorrento Therapeutics inc',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'university_of_life-128',
    productId: 128,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '3a828ae8c0095976a9e4da7d0e3c7bfdddeb87ac',
        sponsorName: 'University of Life',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'inopulse',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'inopulse',
    productId: 129,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '7efcbd9db54765e1aeaf893d6a3ed78f9d70a195',
        sponsorName: 'Bellepheron Therapeutics Inc',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'cytosorb',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'cytosorb',
    productId: 130,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'd550d39fbfcc114bb9424feb7ee3922ee7889355',
        sponsorName: 'CytoSorbents Corporation',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'polytope mab therapy',
    conditionOrDisease: '',
    countries: 'canada',
    countryCodes: 'can',
    currentStatus: 'pre-clinical testing',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes: 'monoclonal antibodies',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'polytope mab therapy',
    productId: 67,
    productType: '',
    repurposed: 'new',
    siteLocations: '',
    sources: [
      'https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html',
      'https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic',
      'https://www.immunoprecise.com/immunoprecises-artificial-intelligence-partner-evqlv-submits-first-panel-of-optimized-antibody-sequences-to-coronavirus-for-polytope-mab-therapy-program/',
      'https://www.immunoprecise.com/immunoprecise-announces-the-launch-of-polytope-mab-therapy-tm-to-tackle-coronavirus-pandemic/',
    ],
    sponsors: [
      {
        sponsorId: '7670240cc18d7cdc6c4cdc1e43d130218caa45c4',
        sponsorName: 'ImmunoPrecise Antibodies Ltd',
      },
      {
        sponsorId: '6eab2ef2c61e3007604b07fb544709610e671afa',
        sponsorName: 'EVQLV',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'monoclonal antibodies',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'ifx-1',
    conditionOrDisease: 'covid19',
    countries: 'germany',
    countryCodes: 'deu',
    currentStatus: 'phase 1',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'protein-based (including monoclonal antibodies)',
    notes: 'monoclonal antibodies',
    numSites: '1',
    otherPartners: '',
    phase: '1',
    preferredName: 'ifx-1',
    productId: 68,
    productType: '',
    repurposed: 'repurposed-approved',
    siteLocations: 'china',
    sources: [
      'https://www.inflarx.de/home/investors/press-releases/03-2020-inflarx-doses-first-patient-in-multicenter-randomized-clinical-trial-in-severe-progressed-covid-19-pneumonia-in-europe-upon-receipt-of-initial-positive-human-data-with-inflarx-s-anti-c5a-technology.html',
      'https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/',
      'https://www.nature.com/articles/d41587-020-00005-z',
      'https://www.inflarx.de/home/research---development/pipeline.html',
      'https://www.inflarx.de/home/investors/press-releases/02-2020-inflarx-announces-positive-initial-data-from-ongoing-phase-iia-open-label-study-with-ifx-1-in-patients-suffering-from-pyoderma-gangraenosum-.html',
      'https://www.genengnews.com/virology/coronavirus/catching-up-to-coronavirus-top-60-treatments-in-development/',
    ],
    sponsors: [
      {
        sponsorId: '8b37254ccb340a35bc492a85125002e78f979b1e',
        sponsorName: 'InflaRx',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'monoclonal antibodies',
    trialId: '',
  },
  {
    brandName: 'aplidin',
    chemicalName: 'plitidepsin',
    conditionOrDisease: 'covid 19',
    countries: 'spain',
    countryCodes: 'esp',
    currentStatus: 'phase 2',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'small molecule',
    notes: 'anti-melanoma agent',
    numSites: '',
    otherPartners: 'csic',
    phase: '2',
    preferredName: 'plitidepsin',
    productId: 69,
    productType: '',
    repurposed: 'repurposed-approved',
    siteLocations: 'spanish hospitals',
    sources: [
      'https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards',
      'https://www.drugbank.ca/drugs/db04977',
      'https://www.researchgate.net/publication/26280244_the_mechanism_of_action_of_plitidepsin',
      'https://www.pharmamar.com/wp-content/uploads/2018/12/pr_approval-aplidin-australia.pdf',
      'https://www.oncozine.com/plitidepsin-a-novel-anti-cancer-agent-possibly-active-against-covid18/',
      'http://pharmamar.com/?lang=en',
      'https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idusfwn2bp1ob',
      'https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6505631/',
      'https://www.thepharmaletter.com/article/pharmamar-says-its-drug-aplidin-could-treat-covid-19',
      'https://www.contractpharma.com/contents/view_breaking-news/2020-03-13/pharmamar-reports-positive-results-for-aplidin-against-coronavirus/',
    ],
    sponsors: [
      {
        sponsorId: 'ec5f02cd738afe63b04534d0cc394af54573dc39',
        sponsorName: 'Pharmamar',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs-immunosupressive',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'ganovo + ritonavir',
    conditionOrDisease: 'covid19',
    countries: 'china',
    countryCodes: 'chn',
    currentStatus: 'phase 2',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'small molecule',
    notes: 'study patients discharged',
    numSites: '',
    otherPartners: 'shaoxing government',
    phase: '2',
    preferredName: 'ganovo + ritonavir',
    productId: 70,
    productType: '',
    repurposed: 'repurposed-approved',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '3799735fca71d687b33e157b0589e09999052c4f',
        sponsorName: 'Ascletis Pharma',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'protease inhibitor',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'arcturus-71',
    productId: 71,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '20dfe597bbef86e0b9719260a7c300a5b0df15ae',
        sponsorName: 'Arcturus',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'avigan,favilavir',
    chemicalName: 'favipiravir',
    conditionOrDisease: 'covid-19',
    countries: 'japan',
    countryCodes: 'jpn',
    currentStatus: 'phase 3',
    indication: 'covid-19',
    interventionType: 'therapeutic',
    moleculeType: 'small molecule',
    notes: 'japan has stockpile of 2 million.',
    numSites: '11',
    otherPartners: '',
    phase: 'not applicable',
    preferredName: 'favipiravir',
    productId: 72,
    productType: '',
    repurposed: 'repurposed-approved',
    siteLocations:
      'anhui medical university affiliated first hospital - hefei - china,guiqiang wang - beijing - china,peking university first hospital - beijing - china,cancer hospital union hospital tongji medical college huazhong university of science and technology - wuhan - china,ezhou central hospital - wuhan - china,huoshenshan hospital of wuhan - wuhan - china,jinyintan hospital of wuhan - wuhan - china,tongji hospital of huazhong university of science and technology - wuhan - china,west hospital union hospital huazhong university of science and technology - wuhan - china,wuhan pulmonary hospital - wuhan - china,zhongnan hospital of wuhan university - wuhan - china',
    sources: [
      'https://www.fujifilm.com/jp/en/news/hq/3211',
      'https://clinicaltrials.gov/ct2/show/nct04310228',
    ],
    sponsors: [
      {
        sponsorId: 'd3f2295022832956ff09046194ed9b4ab9077636',
        sponsorName: 'Fujifilm',
      },
      {
        sponsorId: 'e3b26f3f63704a702040cad0b3d5f4ff56f7360a',
        sponsorName: 'Peking University First Hospital',
      },
    ],
    status: 'ongoing',
    therapeuticApproach: 'antiviral drugs-antiretrovirals',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'zydus_cadila-73',
    productId: 73,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '9e1c8045b7fdc2fe2d635960c9b93dbbdd1a14a7',
        sponsorName: 'Zydus Cadila',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'sinovac-74',
    productId: 74,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '93bef25f8dc322ecb56eae9b00dfed2b3169a709',
        sponsorName: 'Sinovac',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'inactivated vaccine',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'inactivated_vaccine',
    productId: 75,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'e1992462e6978a6ef1bdee8a86f7d513222c1ad6',
        sponsorName: 'Beijing Institute of Biological Products',
      },
      {
        sponsorId: 'ad6a16130480e1a77d5ffb88a5752fdae6685597',
        sponsorName: 'Wuhan Institute of Biological Products',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'codagenix_serum_institute_of_india-76',
    productId: 76,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '4f658739e6abe56363d5f2d9559538ae578e3aad',
        sponsorName: 'Codagenix',
      },
      {
        sponsorId: 'adee3b214297c2f83d459d75e4e295cde4fd187c',
        sponsorName: 'Serum Institute of India',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'dzif__german_center_for_infection_research-77',
    productId: 77,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '42dc4894fcc96aa20e701b0f9bbb2fb79c1f0279',
        sponsorName: 'DZIF  German Center for Infection Research',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'greffex-78',
    productId: 78,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '6c01129b833a3f153fc0408879e5a2bb4bf21b9b',
        sponsorName: 'Greffex',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'adaptvac-79',
    productId: 79,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'b3dd9ec1147ddf57383d3eda6cd2d861e37911df',
        sponsorName: 'AdaptVac',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'expres2ion-80',
    productId: 80,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '0e8712d7220f021dc49eb43e9f943e390e969a92',
        sponsorName: 'ExpreS2ion',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'wrair_usamriid-81',
    productId: 81,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '455288f646569f2165f9af95d690d300bbd182a8',
        sponsorName: 'WRAIR',
      },
      {
        sponsorId: '301d4da21e654a4dac3ab28cf3feba940a10bc5f',
        sponsorName: 'USAMRIID',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'vaxil_bio-82',
    productId: 82,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '54865dacf1194e272ece7152fb33dd51a6489d91',
        sponsorName: 'Vaxil Bio',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'flow_pharma-83',
    productId: 83,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '306b4a5ca7bafa2c8cb1637d2068fec4dcf4c872',
        sponsorName: 'Flow Pharma',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'generex_epivax-84',
    productId: 84,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'cd141551e1601926b871c88dedc02dd8b17de789',
        sponsorName: 'Generex',
      },
      {
        sponsorId: '2b2068ecd13962f5098c0b0cd04aaf01f7c38c14',
        sponsorName: 'EpiVax',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'epivax_university_of_georgia-85',
    productId: 85,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '2b2068ecd13962f5098c0b0cd04aaf01f7c38c14',
        sponsorName: 'EpiVax',
      },
      {
        sponsorId: 'e4bf2c53813e4971a809acf75b015ef7d10cbebc',
        sponsorName: 'University of Georgia',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'heat_biologics_university_of_miami-86',
    productId: 86,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'a71aa5201092a2d85b09f0762d443b8cc4ad066b',
        sponsorName: 'Heat Biologics',
      },
      {
        sponsorId: '0fc2d17219cc99046bce21a2c41bc8215617c73d',
        sponsorName: 'University of Miami',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'baylor_college_of_medicine-87',
    productId: 87,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '41801411fe7d66b24eae2e0411ee409f9ad29507',
        sponsorName: 'Baylor College of Medicine',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'ibio_ccpharming-88',
    productId: 88,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '6627849a10e533013b5778335f809e5b1b1b3243',
        sponsorName: 'iBio',
      },
      {
        sponsorId: 'd14d7aa141ec44e3a13ede2508c4cca5d6b7d619',
        sponsorName: 'CCPharming',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'vidointervac_university_of_saskatchewan-89',
    productId: 89,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '00779c5db9466de70c91f79cb8ce78836132058d',
        sponsorName: 'VIDOInterVac',
      },
      {
        sponsorId: '7ffe768f0f9cf49a08e526fad894319b1b874d64',
        sponsorName: 'University of Saskatchewan',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'oncogen-90',
    productId: 90,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '102fe9bb3724bbad454162ce2f31318baff6facb',
        sponsorName: 'OncoGen',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName:
      'institute_pasteur_themis_university_of_pittsburg_center_for_vaccine_research-91',
    productId: 91,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'a2a15d79e1f0b774dbc631aeed3b73af7f225cfe',
        sponsorName: 'Institute Pasteur',
      },
      {
        sponsorId: '613e550610f0a7b4bbfd4fa0ab61e13afc1f9b01',
        sponsorName: 'Themis',
      },
      {
        sponsorId: '6d4630e0bc4dee4a209f023c333aa4fc055591fc',
        sponsorName: 'University of Pittsburg Center for Vaccine Research',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName:
      'fudan_university_shanghai_jiattong_university_rnacure_biopharma-92',
    productId: 92,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '4567098e44fc907783878b149c6d70d1f14aec40',
        sponsorName: 'Fudan University',
      },
      {
        sponsorId: 'aa6799f660cd49b264d3e155560878bb15e8b804',
        sponsorName: 'Shanghai JiatTong University',
      },
      {
        sponsorId: 'f8f4d45187fd48b7b35c26e73dc0b1c09938f8e0',
        sponsorName: 'RNACure Biopharma',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'china_cdc_tongji_university_stermina-93',
    productId: 93,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '20e19a20e9874c07beba2c307650020c6a63535b',
        sponsorName: 'China CDC',
      },
      {
        sponsorId: '0a82122244646304c943aa942a96ad3ace268562',
        sponsorName: 'Tongji University',
      },
      {
        sponsorId: '30508a3774a3fd8aeb4cf75885e2ee9011d8514f',
        sponsorName: 'Stermina',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'karolinska_institute-94',
    productId: 94,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'a26c2ef25366b153b9c8bb0d553426bbab80d427',
        sponsorName: 'Karolinska Institute',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'reithera-95',
    productId: 95,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '6887e6de5a46033245e0bcb4f49450dcbadd7441',
        sponsorName: 'ReiThera',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'bionet_asia-96',
    productId: 96,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '6a4be0a2fbeb04dd3db2a97fc2f68a2388bb723b',
        sponsorName: 'BioNet Asia',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'immunoprecise-97',
    productId: 97,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'c287fbb2eede11927b6a7b38de9c5e7b1e04b966',
        sponsorName: 'ImmunoPrecise',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'doherty_institute-98',
    productId: 98,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'e8af2a52a069a3c9d2e7076dbd1450dcac577b76',
        sponsorName: 'Doherty Institute',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: 'covid-19',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'tulane_university-99',
    productId: 99,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'b4a99af9eec1a8f807ede0e67dd5e8d77867b245',
        sponsorName: 'Tulane University',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'hoth_therapeutics-100',
    productId: 100,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'a0e1dd25259a873fb5bbf352459b984c718be493',
        sponsorName: 'Hoth Therapeutics',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'dynavax_clover-101',
    productId: 101,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '8b4d210c885dc58c6711e526b8b4bd37c6acfd55',
        sponsorName: 'Dynavax',
      },
      {
        sponsorId: '98d391f3ea6e38dce05de1f6df1b3d708f268eff',
        sponsorName: 'Clover',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'sti-6991',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'sti6991',
    productId: 102,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'd4f038c1fd0e4c52d93147fc334849bc67394496',
        sponsorName: 'Sorrento Therapeutics',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'vtp-500',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'vtp500',
    productId: 103,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '3539cc93ae38ac97613e91267777269795073379',
        sponsorName: 'Vaccitech',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: 'vaccine - prophylactic',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'sanofi_translate_bio-104',
    productId: 104,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '551135a9f6ade78853bbd5fdbd66283c70e2f776',
        sponsorName: 'Sanofi',
      },
      {
        sponsorId: '1ddb247542fcbc349fe829611d29e6ded2b999e7',
        sponsorName: 'Translate Bio',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'nebulized ampion',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'nebulized_ampion',
    productId: 105,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '02881a510323f0cd43a11e035e7be1138b026116',
        sponsorName: 'Ampio Pharmaceuticals',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'piclidenoson',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'piclidenoson',
    productId: 106,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '2ea7e102c17c41b12f5ea330cafbdf8e967c6742',
        sponsorName: 'CanFite BioPharma Ltd',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'fingolimod',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'fingolimod',
    productId: 107,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'bdb-1',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'bdb1',
    productId: 108,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'ecc0feedb452374f3f35ae9224fd597c82fca6a1',
        sponsorName: 'InflaRx NV',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'ryoncil',
    chemicalName: 'remestemcel-l',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'remestemcell',
    productId: 109,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'd4959407d4633b3c9180469947d99a947263aeb9',
        sponsorName: 'Mesoblast Limited',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'actemvra',
    chemicalName: 'tocilizumab',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'tocilizumab',
    productId: 110,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'cc672ac08b0d9e540145295250d172650b81b78c',
        sponsorName: 'Rogers Corporation',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'diammonium',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'diammonium',
    productId: 111,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '828d3ce717e4188e36142a37dde46c7150e54532',
        sponsorName: 'Sino Biopharmaceuticals',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'snx-5542',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'snx5542',
    productId: 131,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '282eaef03c22bad7cc8a8fd8da311711425b1a20',
        sponsorName: 'Esanex',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'mytesi',
    chemicalName: 'crofelemer',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'crofelemer',
    productId: 132,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'c7563c3b7fe4829bad22fa8782140bff9d34561f',
        sponsorName: 'Jaguar Health',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'leibniz_institute-133',
    productId: 133,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '8e15d495d6fb7018df95d75779b82dcd926be20f',
        sponsorName: 'Leibniz Institute',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'allergan-134',
    productId: 134,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '81ce487fc0d3a5b4c58a218b8adceb96a044468f',
        sponsorName: 'Allergan',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'oncoimmune-135',
    productId: 135,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '01bbc68194bde084f23cb9df2a7ae7d59d15b54f',
        sponsorName: 'OncoImmune',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'pulmotect-136',
    productId: 136,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '1eab813cb618e383ce0ca0e7f81c6684b50fdddc',
        sponsorName: 'Pulmotect',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'asan_medical_center-137',
    productId: 137,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '46995ecc0a38eb8057922b33c458f0c5a641c004',
        sponsorName: 'Asan Medical Center',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'digestive_disease_research_institute-138',
    productId: 138,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '4df36b5a59c84e2083f2bc2c1d75bda25e29f290',
        sponsorName: 'Digestive Disease Research Institute',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'doi_yohei-139',
    productId: 139,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '055d27dd32192f82e546e2324220d44b2377d3e2',
        sponsorName: 'Doi Yohei',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'fondation_mediterranee_infection-140',
    productId: 140,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'f504a9b418cd0c0f06bc0337180c16761e95b8b1',
        sponsorName: 'Fondation Mediterranee Infection',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'inserm-141',
    productId: 141,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '0e1ea407af0902261db76719a57a5c127ea53bfe',
        sponsorName: 'INSERM',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'massachusetts_general_hospital-142',
    productId: 142,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '8a365c9b40d6477fb64fadbb35d6bac33dafb436',
        sponsorName: 'Massachusetts General Hospital',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'national_cancer_institute-143',
    productId: 143,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '2ca60c923f9bd40c651529c4a7b5a6972829d31d',
        sponsorName: 'National Cancer Institute',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'national_institute_or_respiratory_diseases-144',
    productId: 144,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'd80856b58ac5220f8bfd50582888e2c18ffc0e7a',
        sponsorName: 'National Institute or Respiratory Diseases',
      },
      {
        sponsorId: '41937b20fbe8c71d9c6c3346aff43c001aa25e33',
        sponsorName: 'Mexico',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'rajavithi_hospital-145',
    productId: 145,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '6929a0f7701affd68fc35e0bb16ed03f8cfbfee6',
        sponsorName: 'Rajavithi Hospital',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'shahid_beheshti_univeristy_of_medical_sciences-146',
    productId: 146,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'eb058ec8d1b15050f17777e54392b41479ffda20',
        sponsorName: 'Shahid Beheshti Univeristy of Medical Sciences',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'synairgen_research_limited-147',
    productId: 147,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '0d3266afcc25af5b518f15e74146cd88dd963d48',
        sponsorName: 'Synairgen Research Limited',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'tehran_university_of_medical_sciences-148',
    productId: 148,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '3d91d8a2763ff7a2305e9571ce331344f8db21d8',
        sponsorName: 'Tehran University of Medical Sciences',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'tokue_yutaka-149',
    productId: 149,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'e34ee0fed8a1cf2adcf0af137c8c46865212e52c',
        sponsorName: 'Tokue Yutaka',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'beijing_chaoyang_hospital_capital_medical_university-150',
    productId: 150,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '2edadb0a368326e19a38c17e17aa31d37ca94581',
        sponsorName: 'Beijing Chaoyang Hospital',
      },
      {
        sponsorId: 'ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073',
        sponsorName: 'Capital Medical University',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'beijing_youan_hospital_capital_medical_university-151',
    productId: 151,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '321cfa99e2d96ffd805132b7d743b6bce706e380',
        sponsorName: 'Beijing Youan Hospital',
      },
      {
        sponsorId: 'ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073',
        sponsorName: 'Capital Medical University',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'capital_medical_university-152',
    productId: 152,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'ffd8a5577b16ce486d568c58bbd8c4ecc8d5b073',
        sponsorName: 'Capital Medical University',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'central_south_hospital_of_wuhan_university-153',
    productId: 153,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '61d51b84b52a8e11bed5095d6b358c893278e9c5',
        sponsorName: 'Central South Hospital of Wuhan University',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'chinese_pla_general_hospital-154',
    productId: 154,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'fd42d18e8b7910f6d46364e1b2fb53ee1912a19b',
        sponsorName: 'Chinese PLA General Hospital',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'chongqing_public_health_medical_center-155',
    productId: 155,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '45c8692c794fd50c930fb0b97c607465d7d554b9',
        sponsorName: 'Chongqing Public Health Medical Center',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'foshan_first_peoples_hospital-156',
    productId: 156,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '0aa5baf3a5bfcd9bd34bc49ddd68b3369a8bd29f',
        sponsorName: 'Foshan First Peoples Hospital',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'health_commission_of_heilongjiang_province-157',
    productId: 157,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '74eb28bb89c6d76ecbdcbb4b00449a43dd0efd98',
        sponsorName: 'Health commission of Heilongjiang province',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: 'azvudine',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'azvudine',
    productId: 158,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '590809afc11f993a1d02526632882469be2ae713',
        sponsorName: 'Henan Provincial Peoples Hospital',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'huilan_zhang-159',
    productId: 159,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'abf659ef96c4f7cef8ec83e1e16ec37d171098bb',
        sponsorName: 'Huilan Zhang',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName:
      'hwa_mei_hospital_university_of_chinese_academy_of_sciences-160',
    productId: 160,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '617b848747bc14a2a9fc203852ab5529565cab2a',
        sponsorName: 'Hwa Mei Hospital',
      },
      {
        sponsorId: 'ac1ac20ca0b9ec951428fe364c421040f1f4829b',
        sponsorName: 'University of Chinese Academy of Sciences',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'jingzhou_first_peoples_hospital-161',
    productId: 161,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'de88121edbf4cca2b6df882b71a3a79995714b11',
        sponsorName: 'Jingzhou First Peoples Hospital',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'peking_union_medical_college_hospital-162',
    productId: 162,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '10172e384c8eaa0f469f305f6d2b50b0eabb14f5',
        sponsorName: 'Peking Union Medical College Hospital',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'peking_university_first_hospital-163',
    productId: 163,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'e3b26f3f63704a702040cad0b3d5f4ff56f7360a',
        sponsorName: 'Peking University First Hospital',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'peoples_hospital_of_guangshan_county-164',
    productId: 164,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '9b38a8623a43ac6813f56ef17b83f2ca2a213237',
        sponsorName: 'Peoples Hospital of Guangshan County',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'qazvin_university_of_medical_sciences-165',
    productId: 165,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '2c3dce78e2656e4bdf014ec95f1f244efcb85b05',
        sponsorName: 'Qazvin University of Medical Sciences',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'qilu_hospital_of_shandong_university-166',
    productId: 166,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '5097a8114e431ac8ebcbd82cdf94884e315a5cba',
        sponsorName: 'Qilu Hospital of Shandong University',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'renmin_hospital_of_wuhan_university-167',
    productId: 167,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '14a2146233138c07a64e0baef6cc949f64c7af25',
        sponsorName: 'Renmin Hospital of Wuhan University',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName:
      'second_affiliated_hospital_of_wenzhou_medical_university-168',
    productId: 168,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '87b385be246abb1a4c3e0d7f6bbe23e811156173',
        sponsorName: 'Second Affiliated Hospital of Wenzhou Medical University',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'shahid_beheshti_university_of_medical_sciences-169',
    productId: 169,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'b58861dc99cd85f531c98907e3577fe93964d0f3',
        sponsorName: 'Shahid Beheshti University of Medical Sciences',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'shanghai_public_health_clinical_center-170',
    productId: 170,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '78190ce5e186ac701c260b91aa1008a6c4b862de',
        sponsorName: 'Shanghai Public Health Clinical Center',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'southeast_university__china-171',
    productId: 171,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '9ba50a6c509f14bcba0e2116a0a021e05e985ae6',
        sponsorName: 'Southeast University  China',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'tangdu_hospital-172',
    productId: 172,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '90580332dd2c5e7458dc3f0dc0ba01024427917e',
        sponsorName: 'TangDu Hospital',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName:
      'the_first_affiliated_hospital_of_fujian_medical_university-173',
    productId: 173,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'beea472f9414420dd2ba494bd1b0dbf60d0df7a7',
        sponsorName:
          'The First Affiliated Hospital of Fujian Medical University',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'tongji_hospital-174',
    productId: 174,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '5b5b8fac5162ad1d88a07970c29180291cab2655',
        sponsorName: 'Tongji Hospital',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'xijing_hospital-175',
    productId: 175,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'c8523547da03b9b3e757de3bc960672aa18072e3',
        sponsorName: 'Xijing Hospital',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'zhiyong_peng-176',
    productId: 176,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '4aa837dcf498f3cc77b727f1990dd1d645311b0b',
        sponsorName: 'ZhiYong Peng',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'peter_doherty_institute_for_infection_and_immunity-177',
    productId: 177,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'a6fe5f8f84da1d7b22c45630250e4e2f8089321f',
        sponsorName: 'Peter Doherty Institute for Infection and Immunity',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'celularity_inc_sorrento_therapeutics_inc-178',
    productId: 178,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'db21bb858ca06c7530b53487f0dd905696244c54',
        sponsorName: 'Celularity Inc',
      },
      {
        sponsorId: '5fc64f72797f9967b8f89cf58d0d24a43168cffc',
        sponsorName: 'Sorrento Therapeutics Inc',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'sti-4920,cmab020',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'sti4920_cmab020',
    productId: 179,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '5fc64f72797f9967b8f89cf58d0d24a43168cffc',
        sponsorName: 'Sorrento Therapeutics Inc',
      },
      {
        sponsorId: 'c9c165926c1b9b7b8832e8afef24f2834d6e595c',
        sponsorName: 'Mabpharm Limited',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'smartpharm_therapeutics_inc_sorrento_therapeutics_inc-180',
    productId: 180,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '99401ebed0fa84553f3dab49ec5651d6e16ebb72',
        sponsorName: 'SmartPharm Therapeutics Inc',
      },
      {
        sponsorId: '5fc64f72797f9967b8f89cf58d0d24a43168cffc',
        sponsorName: 'Sorrento Therapeutics Inc',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'celltrion-181',
    productId: 181,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '625c2965f7108c1ad1edf37eef366aad6b28fbd8',
        sponsorName: 'Celltrion',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'kamada-182',
    productId: 182,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '9573b801f9050224bc124f68819426bce6491fd0',
        sponsorName: 'Kamada',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'swiftscale_biologics-183',
    productId: 183,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'bcb8d1f52e45cce0b2413d1c2485755444633dbb',
        sponsorName: 'Swiftscale Biologics',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: '',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'erasmus_mc_utrecth_university-184',
    productId: 184,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'fe367a0d5ee946a16335321f006255c41d4c8e7b',
        sponsorName: 'Erasmus MC',
      },
      {
        sponsorId: 'e5479b2036f6950930cca1811fbcb4957595d9cd',
        sponsorName: 'Utrecth University',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'prezcobix',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'prezcobix',
    productId: 185,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'arbidol',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'arbidol',
    productId: 186,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: 'deef1b7181395ef02ad3b7cd894fb64716ba0215',
        sponsorName: 'Pharmstandard',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'xofluza',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'xofluza',
    productId: 187,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '7acdde062bf6d75cd4f60fb9c8d60bb3caa89d9a',
        sponsorName: 'Roche',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
  {
    brandName: 'plx cell product',
    chemicalName: '',
    conditionOrDisease: '',
    countries: '',
    countryCodes: 'gbr',
    currentStatus: '',
    indication: '',
    interventionType: '',
    moleculeType: '',
    notes: '',
    numSites: '',
    otherPartners: '',
    phase: '',
    preferredName: 'plx_cell_product',
    productId: 188,
    productType: '',
    repurposed: '',
    siteLocations: '',
    sources: [''],
    sponsors: [
      {
        sponsorId: '6a40a6d08f454a225e8b34e226db476dd5b5be84',
        sponsorName: 'Pluristem',
      },
    ],
    status: '',
    therapeuticApproach: '',
    trialId: '',
  },
]
